AP NEWS

Investigation Report on China’s Montelukast Market, 2018-2022 - ResearchAndMarkets.com

December 4, 2018

DUBLIN--(BUSINESS WIRE)--Dec 4, 2018--The “Investigation Report on China’s Montelukast Market, 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

Montelukast, developed by MSD, is widely used in the treatment of allergic rhinitis and asthma. As a selective leukotriene D4 receptor antagonist, it selectively binds to the leukotrienes in the airway, blocks the action of allergic mediators, reduces airway inflammation, and makes the airway unobstructed.

In 1998, Montelukast sodium tablets (10 mg) and chewable tablets (5 mg) were approved by the FDA and first marketed in the U.S. in the trade name of Singulair. In 2000 and 2002, Montelukast chewable tablets (4 mg) and granules (4 mg) were approved for sale, mainly for the prevention and long-term treatment of asthma in adults and children aged above 2.

According to the market research, from 2005 to 2010, the annual sales value of Montelukast in China grew at a CAGR of more than 40%. As competing products emerged, the growth rate slowed down from 2011 but stays above 10%. In 2017, the market size of Montelukast was about CNY 552 million. The market was dominated by MSD, Lunan Better Pharmaceutical Co., Ltd., and Sichuan Otsuka Pharmaceutical Co., Ltd. Declining in recent years, the market share by sales value of MSD was close to 73%.

According to statistics, there are more than 30 million asthma patients and 300 million to 400 million patients with allergic rhinitis in China. And the numbers will continue to rise with increasingly serious environmental pollution. In China, Montelukast is considered as one of the best anti-asthmatic drugs, which promises huge market potential.

Key Topics Covered:

1. Basic Concept of Montelukast

2. Sales of Montelukast in China, 2013-2017

3. Analysis on Major Montelukast Manufacturers in China, 2013-2017

4. Prices of Montelukast in China, 2017-2018

5. Prospect of China’s Montelukast Market, 2018-2022

Companies Mentioned

Lunan Better Pharmaceutical Co. Ltd MSD Sichuan Otsuka Pharmaceutical Co. Ltd

For more information about this report visit https://www.researchandmarkets.com/research/2xx8bj/investigation?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181204005954/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs,Asthma Drugs

KEYWORD: ASIA PACIFIC CHINA

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/04/2018 02:06 PM/DISC: 12/04/2018 02:06 PM

http://www.businesswire.com/news/home/20181204005954/en

AP RADIO
Update hourly